The U.S. Food and Drug Administration on Tuesday allowed genetic testing company 23andMe to market directly to consumers its test that will help assess three mutations in a common type of breast cancer gene.
The U.S. FDA accepted for review the supplemental BLA of Dupixent (dupilumab) as an add-on maintenance treatment in certain adults and adolescents with moderate-to-severe asthma.
Teva Pharmaceuticals Inc. made more cuts in the United States, this time to real estate holdings. To save money, the company will close its offices in Washington, D.C. and New York City. No jobs were reported to be lost from the cuts.
The U.S. FDA granted San Diego-based Evofem Biosciences Fast Track designation for Amphora vaginal gel to prevent urogenital chlamydia infection in women.
Fast Company recently published The World’s 50 Most Innovative Companies 2018, topping off its edition of the top 350 most innovative companies. Here is a look at the life science companies that made the list.
Chicago-based AbbVie and Cambridge, Mass.-based Voyager Therapeutics inked a collaboration deal to develop treatments for Alzheimer’s disease and other neurodegenerative diseases.
U.S. drug developer Aimmune Therapeutics Inc.’s peanut allergy drug met the main goal of an eagerly awaited late-stage study.
Eli Lilly and its Korean collaborative partner Hanmi Pharmaceutical stopped a Phase II trial on an experimental rheumatoid arthritis treatment after less-than-stellar interim results were examined.
Shares of Pacira Pharmaceuticals plunged more than 15 percent after the company revealed a U.S. Food and Drug Administration advisory panel recommended against approving expanded use of the company’s pain treatment Exparel.
U.S. regulators proposed lowering the bar for clinical trial success for experimental Alzheimer’s drugs.